Browse
Submit Data
Databases
API
Help

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

ABSTRACT: The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and who are not eligible to enroll in clinical studies designed to support the development and registration of tabelecleucel.

DISEASE(S): Epstein-barr Virus-associated Lymphoproliferative Disease (ebv+ Lpd) With Primary Immunodeficiency (pid),Stem Cell Transplant Complications,Nasopharyngeal Carcinoma,Epstein-barr Virus-associated Lymphoproliferative Disease (ebv+ Lpd) With Acquired Immunodeficiency (aid),Viremia,Lymphoproliferative Disorders,Epstein-barr Virus (ebv) Infections,Epstein-barr Viremia,Solid Organ Transplant Complications,Lymphoma,Leiomyosarcoma (lms),Ebv+ Associated Lymphoma,Primary Immunodeficiency Diseases,Immunologic Deficiency Syndromes,Lymphoma, Aids-related,Ebv+ Associated Post-transplant Lymphoproliferative Disease (ebv+ Ptld),Leiomyosarcoma,Nasopharyngeal Carcinoma (npc),Epstein-barr Virus Infections,Virus Diseases

PROVIDER: 2218995 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Individual Patient Expanded Access to CA102N

Project description:This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.

| 2708903 | ecrin-mdr-crc

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Project description:The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

| 2352905 | ecrin-mdr-crc

An Expanded Access Program for AM0010 (Pegilodecakin)

Project description:This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.

| 2275175 | ecrin-mdr-crc

Photodynamic oncolytic virus therapy for central nervous system malignancies

Project description:The goal of the study was to determine whether photodynamic oncolytic virus therapy of glioblastoma and malignant meningioma xenografts in mice alters transciptomics associated with efficacy. RNA sequencing was used from tumors treated with PBS, laser, G47delta-KillerRed, and G47delta-KillerRed and laser, which is photodynamic oncolytic virus therapy.

2023-01-18 | GSE222895 | GEO

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Project description:RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells. PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.

| 2005372 | ecrin-mdr-crc

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Project description:This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.

| 2343718 | ecrin-mdr-crc

The Microenvironment in Epstein-Barr Virus-Associated Malignancies.

Project description: Not available

| S-EPMC6027429 | biostudies-other

Infection of RoNi cells with Sendai Cantell virus, MARV371bat virus, and VP35 mutant MARV371bat-R301A virus at MOI of 1.0

Project description:Study was performed in order to determine the scope of antiviral response of Rousettus aegyptiacus-derived fibroblasts to Sendai and Marburg virus infection. This study aids in understanding the function of the expanded immune repertoire of Rosettus aegyptiacus.

2018-11-01 | GSE117367 | GEO

adeno-associated virus

Project description:adeno-associated virus Raw sequence reads

| PRJNA310351 | ENA

Impeding transcription of expanded microsatellite repeats by deactivated Cas9

Project description:Transcription of expanded microsatellite repeats is associated with multiple human diseases, including myotonic dystrophy, Fuchs’ endothelial corneal dystrophy, and C9orf72-ALS/FTD. Eliminating or reducing production of RNA and proteins arising from these expanded loci holds therapeutic benefit. Here, we tested the hypothesis that a deactivated form of the Cas9 enzyme impedes transcription across expanded microsatellites. We observed a repeat length-, PAM-, and strand-dependent reduction in the abundance of repeat-containing RNAs upon targeting dCas9 directly to repeat sequences. Aberrant splicing patterns were rescued in DM1 cells, and production of RAN peptides characteristic of DM1, DM2, and C9orf72-ALS/FTD cells was drastically decreased. Systemic delivery of dCas9/gRNA by adeno-associated virus led to reductions in pathological RNA foci, rescue of chloride channel 1 protein expression, and decreased myotonia. These observations suggest that transcription of microsatellite repeat-containing RNAs is more sensitive to perturbation than transcription of other RNAs, indicating potentially viable strategies for therapeutic intervention.

2017-09-20 | GSE103997 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data